Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ETCompany ParticipantsBen R.

Full transcript - Recursion Pharmaceuticals Inc (RXRX) Q2 2025: Chris Gibson, Co-Founder and CEO, Recursion Pharmaceuticals: Recursion’s q two twenty twenty five earnings call.

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.4 per share a year ago ...

From a technology perspective, Recursion continued the rollout of Recursion OS 2.0, a platform upgrade integrating Exscientia’s AI-driven chemistry capabilities and large-scale multimodal ...

On August 5, 2025, Recursion Pharmaceuticals reported its second quarter 2025 financial results and business updates, highlighting a $7 million milestone achieved with Sanofi and advancements in ...